Re: ABO Blood Group and the Risk of Pancreatic Cancer

Dandona, Monica; Gao, Feng; Linehan, David C.; Wang‐Gillam, Andrea

doi:10.1093/jnci/djp447

Cited by 14 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since risk factors may also have prognostic significance for pancreatic cancer, as suggested (27), we addressed the hypothesis that ABO blood types and the genetic variability at the locus could be implicated in patient survival. To date, this has been examined only in studies with a smaller sample size than ours (16,17) with inconsistent results. The samples from Germany partially overlap with those used in a recent study (28).…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

et al. 2013

View full text Add to dashboard Cite

Abstract. There is strong epidemiologic evidence indicating that common genetic variability could be implicated in pancreatic cancer risk and, to date, various loci have been proposed. In particular, there is increasing evidence of the involvement of ABO gene variability and pancreatic cancer risk. In a large multicentric study of 1,028 pancreatic ductal adenocarcinoma cases and 2,257 controls in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium, we investigated the suggested association with increased risk for carriers of single nucleotide polymorphisms (SNPs) determining the A or B allele in comparison with the O allele, which encodes for a non-functional enzyme. Since glycosyltransferase activity, encoded by ABO, is higher for the A1 variant compared with the A2 variant, we investigated the hypothesis that A1 carriers were at an increased risk of pancreatic cancer. In our analysis, carriers of the A1 were indeed at greater risk of developing the disease. In addition, we investigated the possible influence that genetic variability at the ABO locus may have in pancreatic cancer survival, but we observed no effect in our population.

show abstract

Section: Discussionmentioning

confidence: 87%

“…The carriers of the A or B allele show an increased risk of pancreatic cancer (11,12). A small number of studies have also tested the genetic variability of the locus with the aggressiveness of the disease and survival of patients, with inconsistent results (15)(16)(17).…”

Section: Introductionmentioning

confidence: 99%

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The available evidence on the prognostic value of AB0 blood group in patients with pancreatic cancer has been conflicting. In a study on 417 patients Dandona et al confirmed the increased risk for the development of pancreatic cancer in patients with blood groups others than 0, but did not observe a significant effect of AB0 blood group on overall survival [13]. Ben et al also confirmed the reduced incidence of pancreatic cancer in patients with blood group 0 in their cohort study of 1431 Han Chinese patients [10].…”

Section: Discussionmentioning

confidence: 99%

“…To date, only two studies have correlated AB0 blood group status with survival of pancreatic cancer patients and their results are inconsistent [10,13]. The importance of blood group antigens for disease progression in pancreatic cancer is underlined by studies that demonstrated a prognostic value of Carbohydrate 19–9 (CA19-9) in patients with resectable [14-16] and advanced disease [17,18].…”

Section: Introductionmentioning

confidence: 99%

AB0 blood group and prognosis in patients with pancreatic cancer

et al. 2012

View full text Add to dashboard Cite

Background Although blood group 0 is associated with a reduced risk of pancreatic cancer, little is known about the role of AB0 blood group antigens in disease progression. We assessed the prognostic relevance of AB0 blood status in a large cohort of patients with resected pancreatic cancer. Methods A total of 627 patients, who underwent resection for pancreatic ductal adenocarcinoma between October 2001 and December 2008 were enrolled. The relationship between AB0 blood group status and outcome was analyzed using univariate and multivariate Cox regression analyses. Results In patients with pancreatic cancer the incidence of blood group 0 (31%) was lower compared to 13.044 patients without pancreatic cancer (38%) (p = 0.0005). There were no significant differences in clinicopathologic characteristics among patients with different AB0 blood groups. The 3-year and 5-year overall survival rates were 29% and 14%. On univariate analysis AB0 blood group status did not correlate with survival (p = 0.39). Multivariate analysis, however, revealed a favorable and independent impact of blood group 0 on survival (Hazard ratio 0.78; 95% confidence interval 0.62 – 0.99; p = 0.037). Conclusion AB0 blood group status is associated independently with the prognosis of patients with resected pancreatic cancer.

show abstract

“…Blood group type O has been associated with well-differentiated tumors, while patients with esophageal carcinoma and AB blood type presented larger tumor sizes and more advanced TNM staging [39]. A study of patients with pancreatic cancer demonstrated an increased incidence of the disease among persons with non-O blood types [40,41]. Women having the AB histoblood type group and Rh-negative factor presented a higher frequency of endometrial carcinoma [42].…”

Section: Discussionmentioning

confidence: 99%

Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes

et al. 2010

View full text Add to dashboard Cite

ABH and Lewis antigen expression has been associated with cancer development and prognosis, tumor differentiation, and metastasis. Considering that invasive ductal breast carcinoma (IDC) presents multiple molecular alterations, the aim of the present study was to determine whether the polymorphism of ABO, Lewis, and Secretor genes, as well as ABO phenotyping, could be associated with tumor differentiation and lymph nodes metastasis. Seventy-six women with IDC and 78 healthy female blood donors were submitted to ABO phenotyping/genotyping and Lewis and Secretor genotyping. Phenotyping was performed by hemagglutination and genotyping by the polymerase chain reaction with sequence-specific primers. ABO, Lewis, and Secretor genes were classified by individual single nucleotide polymorphism at sites 59, 1067, 202, and 314 of the Lewis gene, 428 of the Secretor gene, and 261 (O1 allele), 526 (O2 and B allele), and 703 (B allele). No association was found between breast cancer and ABO antigen expression (P = 0.9323) or genotype (P = 0.9356). Lewis-negative genotype was associated with IDC (P = 0.0126) but not with anatomoclinical parameters. Nonsecretor genotype was associated with axillary lymph node metastasis (P = 0.0149). In conclusion, Lewis and Secretor genotyping could be useful to predict respectively breast cancer susceptibility and axillary lymph nodes metastasis.

show abstract

Re: ABO Blood Group and the Risk of Pancreatic Cancer

Cited by 14 publications

References 6 publications

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

AB0 blood group and prognosis in patients with pancreatic cancer

Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes

Contact Info

Product

Resources

About